Jiangsu Recbio Technology Co., Ltd. (2179.HK)
HKD 8.0
(-3.38%)
HKD 8.0
(-3.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.11 Billion CNY | 69.88% |
| 2022 | 656.52 Million CNY | 166.96% |
| 2021 | 245.92 Million CNY | -88.04% |
| 2020 | 2.05 Billion CNY | 175.54% |
| 2019 | 746.09 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.22 Billion CNY | 0.0% |
| 2024 Q1 | 1.22 Billion CNY | 9.65% |
| 2023 Q1 | 889.98 Million CNY | 35.56% |
| 2023 FY | 1.11 Billion CNY | 69.88% |
| 2023 Q4 | 1.11 Billion CNY | 0.0% |
| 2023 Q3 | 1.11 Billion CNY | 25.32% |
| 2023 Q2 | 889.98 Million CNY | 0.0% |
| 2022 Q2 | 403.72 Million CNY | 0.0% |
| 2022 Q1 | 403.72 Million CNY | 64.17% |
| 2022 FY | 656.52 Million CNY | 166.96% |
| 2022 Q4 | 656.52 Million CNY | 0.0% |
| 2022 Q3 | 656.52 Million CNY | 62.62% |
| 2021 Q4 | 245.92 Million CNY | 23.91% |
| 2021 FY | 245.92 Million CNY | -88.04% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 Q3 | 198.46 Million CNY | 0.0% |
| 2020 Q4 | 2.05 Billion CNY | 0.0% |
| 2020 FY | 2.05 Billion CNY | 175.54% |
| 2019 FY | 746.09 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -629.844% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 84.198% |